Accessory pancreas

Summary

Accessory pancreas (MONDO:0019034) is a disease. A subtype of pancreas disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	accessory pancreas
Mondo ID	MONDO:0019034
MeSH	C536003
Orphanet	674
ICD-11	240534435
SNOMED CT	79037006
UMLS	C0266268
MedGen	82737
GARD	0000454
Is cancer (heuristic)	no

Also known as: pancreas accessorium

Disease family

This is a subtype of pancreas disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder › accessory pancreas

Related subtypes (13): pancreatic steatorrhea, pancreatic mucinous ductal ectasia, exocrine pancreatic insufficiency, endocrine pancreas disorder, pancreatitis, annular pancreas, pancreatic triacylglycerol lipase deficiency, follicular cholangitis and pancreatitis, congenital pancreatic cyst, recurrent acute pancreatitis, pancreatic neoplasm, acinar cystic transformation of the pancreas, lymphoepithelial cyst of the pancreas

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.